Top

Published in:

01-10-2014 | Urology - Original Paper

The impact of abdominal aortic calcification and visceral fat obesity on lower urinary tract symptoms in patients with benign prostatic hyperplasia

Authors: Tadasu Motoya, Seiji Matsumoto, Satoshi Yamaguchi, Naoki Wada, Atsushi Numata, Hiroaki Osanai, Hidehiro Kakizaki

Published in: International Urology and Nephrology | Issue 10/2014

Abstract

Objectives

To investigate the impact of abdominal aortic calcification and visceral fat area (VFA) on lower urinary tract symptoms (LUTS) and clinical parameters in patients with benign prostatic hyperplasia (BPH).

Methods

We retrospectively studied 250 patients with LUTS associated with BPH. Each participant was examined with routine examination including measurement of various data; (1) voided volume (VV), maximum urinary flow rate on free uroflowmetry, (2) postvoid residual urine volume and prostate volume using transabdominal ultrasound, (3) International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS), and (4) aortic calcification index (ACI) and VFA were measured by abdominal CT.

Results

Mean age of the patients was 72.4 ± 9.6 years. ACI significantly correlated with VV (P = 0.0392) and tended to correlate with maximum urinary flow rate, while ACI did not correlate with subjective symptoms. VFA significantly correlated with nocturia score of IPSS (P = 0.0177) and frequency score of OABSS (P = 0.0166) and tended to correlate with urgency score of IPSS and maximum urinary flow rate.

Conclusions

Aortic calcification index (ACI) correlated with only objective parameters, while VFA correlated with only storage symptoms. This study suggested that abdominal aortic calcification and VFA have certain influence on LUTS and clinical parameters in patients with BPH.

Parsons JK, Sarma AV, McVary K, Wei JT (2009) Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 182:S27–S31PubMedCrossRef

Kirby MG, Wagg A, Cardozo L et al (2010) Overactive bladder: is there a link to the metabolic syndrome in men? Neurourol Urodyn 29:1360–1364PubMedCrossRef

Alvarez GE, Alvarez GE, Beske SD et al (2002) Sympathetic neural activation in visceral obesity. Circulation 106:2533–2536PubMedCrossRef

McVary KT, Rademaker A, Lloyd GL, Gann P (2005) Autonomic nervous system overactivity in men LUTS secondary to BPH. J Urol 174:1327–1333PubMedCrossRef

Matsumoto S, Kakizaki H (2012) Causative significance of bladder blood flow in lower urinary tract symptoms. Int J Urol 19:20–25PubMedCrossRef

Ponholzer A, Temml C, Wehrberger C et al (2006) The association between vascular risk factors and LUTS in both sexes. Eur Urol 50:581–586PubMedCrossRef

Azadzoi KM, Tarcan T, Kozlowski R et al (1999) Overactivity and structural changes in the chronically ischemic bladder. J Urol 162:1768–1778PubMedCrossRef

Yoshida M, Masunaga K, Nagata T et al (2010) The effects of chronic hyperlipidemia on bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits. Neurourol Urodyn 29:1350–1354PubMedCrossRef

Nomiya M, Yamaguchi O, Andersson KE et al (2012) The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in rats. Neurourol Urodyn 31:195–200PubMedCrossRef

10.

Nomiya M, Sagawa K, Yazaki J et al (2012) Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia. Neurourol Urodyn 31:185–189PubMedCrossRef

11.

Motoya T, Matsumoto S, Yamaguchi S et al (2011) Visceral fat is a significant risk factor of storage symptoms in patients with BPH/LUTS. In: Proceedings of the 41st annual meeting of the International Continence Society, Glasgow, UK, abstract no. 421, p 112

12.

Matsumoto S, Wada N, Motoya T et al (2011) The impact of abdominal aortic calcification and visceral fat obesity on bladder blood flow and lower urinary tract symptoms in patients with benign prostatic hyperplasia. In: Proceedings of the 41st annual meeting of the International Continence Society, Glasgow, UK, abstract no. 301, p 104

13.

Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology 68:318–323PubMedCrossRef

14.

Yamaguchi O, Nishizawa O, Takeda M et al (2009) Clinical guidelines for overactive bladder. Int J Urol 16:126–142PubMedCrossRef

15.

Nitta K, Akiba T, Uchida K et al (2003) The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42:303–309PubMedCrossRef

16.

Ohashi N, Yamamoto H, Horiguchi J et al (2009) Visceral fat accumulation as a predictor of coronary artery calcium as assessed by multislice computed tomography in Japanese patients. Atherosclerosis 202:192–199PubMedCrossRef

17.

Mariappan P, Chong WL (2006) Prevalence and correlations of lower urinary tract symptoms, erectile dysfunction and incontinence in men from a multiethnic Asian population: results of a regional population-based survey and comparison with industrialized nations. BJU Int 98:264–268

18.

Seim A, Hoyo C, Ostbye T, Vatten L (2005) The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 96:88–92PubMedCrossRef

19.

Joseph MA, Harlow SD, Wei JT et al (2003) Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 157:906–914PubMedCrossRef

20.

Wong SY, Woo J, Hong A et al (2006) Risk factors for lower urinary tract symptoms in southern Chinese men. Urology 68:1009–1014PubMedCrossRef

21.

Tomita K, Mizoue T, Matsumoto T (2009) Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers. Int J Urol 16:493–498PubMedCrossRef

22.

Pinggera GM, Mitterberger M, Steiner E et al (2008) Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int 102:470–474PubMedCrossRef

23.

Bartsch G, Strasser H, De EJ et al (2008) Pelvic ischemia is measurable and symptomatic in patients with coronary artery disease: a novel application of dynamic contrast-enhanced magnetic resonance imaging. J Sex Med 5:2635–2645CrossRef

24.

Wada N, Watanabe M, Kita M et al (2012) Analysis of bladder vascular resistance before and after prostatic surgery in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Neurourol Urodyn 31:659–663PubMedCrossRef

25.

Tarcan T, Azadzoi KM, Siroky MB et al (1998) Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 82(Suppl. 1):26–33PubMedCrossRef

26.

Takahashi N, Shishido K, Sato Y et al (2012) The association between severity of atherosclerosis and lower urinary tract function in male patients with lower urinary tract symptoms. LUTS 4:9–13

27.

Kaplan SA (2006) Male pelvic health: a urological call to arms. J Urol 176:2351–2352PubMedCrossRef

28.

Rohrmann S, Smit E, Giovannucci E, Platz EA (2004) Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 159:390–397PubMedCrossRef

Title: The impact of abdominal aortic calcification and visceral fat obesity on lower urinary tract symptoms in patients with benign prostatic hyperplasia
Authors: Tadasu Motoya
Seiji Matsumoto
Satoshi Yamaguchi
Naoki Wada
Atsushi Numata
Hiroaki Osanai
Hidehiro Kakizaki
Publication date: 01-10-2014
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 10/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-014-0757-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2014

Different outcomes of peritoneal catheter percutaneous placement by nephrologists using a trocar versus the Seldinger technique: the experience of two Brazilian centers

Comparison of novel risk factors for cardiovascular disease between hemodialysis patients with and without protein-energy wasting

Treatment of renal parapelvic cysts with a flexible ureteroscope

The optimal timing of continuous renal replacement therapy for patients with sepsis-induced acute kidney injury

Effects of sensory neuron-specific receptor agonist on bladder function in a rat model of cystitis induced by cyclophosphamide

Liposomal inhibition of acrolein-induced injury in rat cultured urothelial cells

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials